Skip to content

GLP-1s & incretins · Metabolic & endocrine

Lixisenatide

A once-daily GLP-1 receptor agonist for glycaemic control in type 2 diabetes — shorter-acting than the weekly agents that dominate headlines.

L5Practice-changingApproved medicineApprovedHigh confidenceLast reviewed 2026-08-23
SC injection

Also known as: Adlyxin, Lyxumia

Evidence passport

Last reviewed 2026-08-23

Evidence level
L5Practice-changing
Confidence
High confidence
Human efficacy
80/100
Human safety
78/100
Regulatory status
Approved medicine
Development
Approved
Routes
SC injection
Evidence base
Includes human data
Furthest stage
Approved
Source curation
Sources fully curated
Clinical maturity
Established GLP-1 medicine

Overview

Human evidence80/100
Preclinical evidence78/100
Human safety evidence78/100

Clinical maturity: Established GLP-1 medicine

Routes & formulations

Studied / approved routes

SC injection

The approved product is a once-daily subcutaneous injection; schedules differ across the GLP-1 class.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

Approved

What it is

An exendin-4-derived GLP-1-receptor agonist peptide with a shorter duration of action than weekly GLP-1 medicines.

What people claim

  • Improves glycaemic control in type 2 diabetes

What the evidence actually says

The trial programme supporting approval included a cardiovascular-outcomes trial (ELIXA) that established cardiovascular safety in a high-risk population without showing the event reduction seen with some other class members — an honest reminder that GLP-1s are not interchangeable.

Human evidence

  • Pivotal randomised glycaemic-control trials.
  • ELIXA cardiovascular-outcomes trial in type 2 diabetes after acute coronary syndrome.

Preclinical evidence

  • GLP-1-receptor pharmacology.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • GLP-1-receptor agonism: glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying.

Safety and unknowns

  • Labelled class effects include gastrointestinal symptoms and pancreatitis warnings.
  • Combination with insulin secretagogues raises hypoglycaemia risk, as labelled.

Cancer relevance

No concern identified

No established human cancer signal within approved use.

Regulatory status

FDA-approved (Adlyxin) as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes; also marketed in some regions as Lyxumia.

Evidence grade

L5Practice-changingHigh confidence

Replicated large randomised trials, pivotal Phase 3 programmes, or a major regulatory decision.

What would change our rating?

  • Not applicable at this evidence tier.

References and sources

Sources fully curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

No recorded changes yet. Baseline position set on 2026-08-23.